XTL Biopharmaceuticals has reported positive results from a Phase II study of the hepatitis treatment HepeX-B.
In the study, HepeX-B was studied as maintenance therapy to prevent re-infection with hepatitis B in patients with liver transplants. Data from liver transplant patients who were treated with monthly infusions of 20- or 40-mg HepeX-B versus 5000 IU of HBIg showed that patients with either dose of HepeX-B experienced no evidence of viral re-infection. The data also showed fewer and less serious adverse experiences reported in both HepeX-B groups as compared to the HBIg group, although the differences were not statistically significant given the number of patients in the trial. Patients who were treated with HepeX-B as well as HBIg also received concurrent HBV polymerase inhibitor.